001     172519
005     20240229133720.0
024 7 _ |a 10.3390/nu13093132
|2 doi
024 7 _ |a pmid:34579010
|2 pmid
024 7 _ |a pmc:PMC8470201
|2 pmc
024 7 _ |a altmetric:113183617
|2 altmetric
037 _ _ |a DKFZ-2021-02067
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Aglago, Elom K
|b 0
245 _ _ |a Dietary Advanced Glycation End-Products and Colorectal Cancer Risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) Study.
260 _ _ |a Basel
|c 2021
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1633686691_25366
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Dietary advanced glycation end-products (dAGEs) have been hypothesized to be associated with a higher risk of colorectal cancer (CRC) by promoting inflammation, metabolic dysfunction, and oxidative stress in the colonic epithelium. However, evidence from prospective cohort studies is scarce and inconclusive. We evaluated CRC risk associated with the intake of dAGEs in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Dietary intakes of three major dAGEs: Nε-carboxy-methyllysine (CML), Nε-carboxyethyllysine (CEL), and Nδ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were estimated in 450,111 participants (median follow-up = 13 years, with 6162 CRC cases) by matching to a detailed published European food composition database. Hazard ratios (HRs) and 95% confidence intervals (CIs) for the associations of dAGEs with CRC were computed using multivariable-adjusted Cox regression models. Inverse CRC risk associations were observed for CML (HR comparing extreme quintiles: HRQ5vs.Q1 = 0.92, 95% CI = 0.85-1.00) and MG-H1 (HRQ5vs.Q1 = 0.92, 95% CI = 0.85-1.00), but not for CEL (HRQ5vs.Q1 = 0.97, 95% CI = 0.89-1.05). The associations did not differ by sex or anatomical location of the tumor. Contrary to the initial hypothesis, our findings suggest an inverse association between dAGEs and CRC risk. More research is required to verify these findings and better differentiate the role of dAGEs from that of endogenously produced AGEs and their precursor compounds in CRC development.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a advanced glycation end-products
|2 Other
650 _ 7 |a colorectal cancer
|2 Other
650 _ 7 |a dietary exposure
|2 Other
650 _ 7 |a dietary glycation compounds
|2 Other
700 1 _ |a Mayén, Ana-Lucia
|b 1
700 1 _ |a Knaze, Viktoria
|b 2
700 1 _ |a Freisling, Heinz
|0 0000-0001-8648-4998
|b 3
700 1 _ |a Fedirko, Veronika
|b 4
700 1 _ |a Hughes, David J
|0 0000-0003-1668-8770
|b 5
700 1 _ |a Jiao, Li
|0 0000-0002-0237-0262
|b 6
700 1 _ |a Eriksen, Anne Kirstine
|b 7
700 1 _ |a Tjønneland, Anne
|0 0000-0003-4385-2097
|b 8
700 1 _ |a Boutron-Ruault, Marie-Christine
|b 9
700 1 _ |a Rothwell, Joseph A
|b 10
700 1 _ |a Severi, Gianluca
|b 11
700 1 _ |a Kaaks, Rudolf
|0 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
|b 12
|u dkfz
700 1 _ |a Katzke, Verena
|0 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
|b 13
|u dkfz
700 1 _ |a Schulze, Matthias B
|0 0000-0002-0830-5277
|b 14
700 1 _ |a Birukov, Anna
|0 0000-0002-8306-3351
|b 15
700 1 _ |a Palli, Domenico
|0 0000-0002-5558-2437
|b 16
700 1 _ |a Sieri, Sabina
|0 0000-0001-5201-172X
|b 17
700 1 _ |a Santucci de Magistris, Maria
|b 18
700 1 _ |a Tumino, Rosario
|b 19
700 1 _ |a Ricceri, Fulvio
|b 20
700 1 _ |a Bueno-de-Mesquita, Bas
|b 21
700 1 _ |a Derksen, Jeroen W G
|0 0000-0002-2973-5583
|b 22
700 1 _ |a Skeie, Guri
|0 0000-0003-2476-4251
|b 23
700 1 _ |a Gram, Inger Torhild
|0 0000-0002-0031-4152
|b 24
700 1 _ |a Sandanger, Torkjel
|b 25
700 1 _ |a Quirós, J Ramón
|b 26
700 1 _ |a Luján-Barroso, Leila
|0 0000-0001-6224-1764
|b 27
700 1 _ |a Sánchez, Maria-Jose
|b 28
700 1 _ |a Amiano, Pilar
|b 29
700 1 _ |a Chirlaque, María-Dolores
|b 30
700 1 _ |a Gurrea, Aurelio Barricarte
|b 31
700 1 _ |a Johansson, Ingegerd
|0 0000-0002-9227-8434
|b 32
700 1 _ |a Manjer, Jonas
|b 33
700 1 _ |a Perez-Cornago, Aurora
|b 34
700 1 _ |a Weiderpass, Elisabete
|0 0000-0003-2237-0128
|b 35
700 1 _ |a Gunter, Marc J
|b 36
700 1 _ |a Heath, Alicia K
|0 0000-0001-6517-1300
|b 37
700 1 _ |a Schalkwijk, Casper G
|b 38
700 1 _ |a Jenab, Mazda
|b 39
773 _ _ |a 10.3390/nu13093132
|g Vol. 13, no. 9, p. 3132 -
|0 PERI:(DE-600)2518386-2
|n 9
|p 3132
|t Nutrients
|v 13
|y 2021
|x 2072-6643
909 C O |o oai:inrepo02.dkfz.de:172519
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 12
|6 P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 13
|6 P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2021
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NUTRIENTS : 2019
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-05-04
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2021-05-04
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-05-04
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-05-04
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-05-04
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-05-04
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-05-04
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-05-04
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l C020 Epidemiologie von Krebs
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21